financetom
Business
financetom
/
Business
/
Goldman Sachs says deal outlook is good, but timing is uncertain
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman Sachs says deal outlook is good, but timing is uncertain
May 29, 2025 7:29 AM

NEW YORK (Reuters) -Goldman Sachs ( GS ) President John Waldron said on Thursday that the outlook for investment banking remains "quite good."

The bank's pipeline for deals worldwide is strong despite uncertainty over timing as U.S. tariff policies roil markets and stall activity, he told investors at a conference.

"Our investment banking business is very strong, and I think the outlook remains quite good," Waldron said. "The pipeline is strong all over the world... but as we've already said, the element of volatility makes it hard" to predict when deals will materialize.

Corporate clients have a positive bias toward transactions and are still holding discussions about mergers, acquisitions and raising capital, Waldron said. Despite a broader slump in M&A, he cited a 30% increase in large deals valued at more than $500 million in the year to date as evidence of the market's resilience.

"Obviously in the second quarter it's been much slower than in the first... Nonetheless, even post-Liberation Day, we've worked on a number of very sizeable, important M&A transactions."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hong Kong regulator fines UBS $1 million over investor classification errors
Hong Kong regulator fines UBS $1 million over investor classification errors
Oct 20, 2025
HONG KONG, Oct 20 (Reuters) - Hong Kong's Security Regulator (SFC) said on Monday that it had reprimanded Swiss bank UBS AG and fined it HK$8 million ($1.03 million) for misclassifying its clients' professional investor status for more than 12 years. A total of 560 joint accounts booked or managed in Hong Kong by the bank were misclassified, the regulator...
Exelixis Reports Detailed Results of Phase 3 Trial of Cancer Combo Treatment; Shares Down Pre-Bell
Exelixis Reports Detailed Results of Phase 3 Trial of Cancer Combo Treatment; Shares Down Pre-Bell
Oct 20, 2025
05:38 AM EDT, 10/20/2025 (MT Newswires) -- Exelixis ( EXEL ) on Monday reported detailed results of a phase 3 trial of zanzalintinib in combination with atezolizumab versus regorafenib in patients with previously treated non-microsatellite instability-high metastatic colorectal cancer. The median overall survival in the intention-to-treat population was 10.9 months with the combination versus 9.4 months with regorafenib at a...
Russian titanium producer VSMPO-AVISMA to cut working week for some staff
Russian titanium producer VSMPO-AVISMA to cut working week for some staff
Oct 20, 2025
MOSCOW, Oct 20 (Reuters) - Russia's VSMPO-AVISMA , the world's biggest producer of titanium, said on Monday that it plans to switch to a four-day working week for some employees not directly involved in production. It is planned to transfer some employees who are not involved in key production processes, mainly administrative staff, to a four-day working week, the company...
Summit Says Ivonescimab Demonstrates 'Significant' Improvement in Progression-Free Survival in Phase 3 Lung Cancer Trial
Summit Says Ivonescimab Demonstrates 'Significant' Improvement in Progression-Free Survival in Phase 3 Lung Cancer Trial
Oct 20, 2025
05:19 AM EDT, 10/20/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Sunday that its ivonescimab product candidate, in combination with chemotherapy, demonstrated a statistically significant improvement in progression-free survival compared with tislelizumab plus chemotherapy in a phase 3 study of the combination therapy in advanced squamous non-small cell lung cancer. The company said the findings were based on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved